BTG, the specialty pharmaceuticals company, has announced its interim results for the six months ended September 30, 2009.
Pre-tax profits dipped 29 percent to 2.4 million pounds on revenues that rose 59 percent to 47.9 million pounds in the six months to September 30.
The surge in revenues came from the addition of Protherics, the drug group with which BTG merged last year.
The total revenues comprised royalties of 32 million pounds from the drug maker's haemophilia treatment and its two-part hip cup used in hip replacement operations.
The group also made $16 million in product sales of both its Crofab treatment for snakebites and Digifab, which treats overdoses of cardiac drugs.
• Revenue of £47.9 million
• Gross profit of £32.3 million
• Profit before tax of £2.4 million
• Cash and cash equivalents at September 30 of £79.2 million
Edited by Ellie Duncan